Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Top Page
Lifecore Biomedical
(NASDAQ:LFCR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.50
▼(-41.63% Downside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak/unstable financial performance (ongoing losses and high leverage) and bearish technical trends (below key moving averages with negative MACD). This is partially offset by an improving operational narrative from the latest earnings call (revenue growth, adjusted EBITDA improvement, cost reductions) and recently improved cash generation, though valuation remains challenged due to negative earnings.
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$176.89M
Dividend YieldN/A
Average Volume (3M)204.26K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth0.47%
EPS Growth-430.88%
CountryUS
Employees524
SectorN/A
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,477,386
10 Day Avg. Volume178,832
30 Day Avg. Volume204,257
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)175.14
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit6.41
Enterprise Value/Ebitda-142.87
Forecast
1Y Price Target
$6.50Price Target Upside-15.69% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lifecore Biomedical Business Overview & Revenue Model
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. Th...
How the Company Makes Money
Lifecore primarily makes money by providing outsourced development and manufacturing services to biopharmaceutical and medical product companies. Its core revenue stream is service revenue tied to (1) CDMO development work (e.g., formulation and p...
Lifecore Biomedical Earnings Call Summary
Earnings Call Date:Mar 16, 2026
(Q5-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive tone: strong revenue growth (+26%), a meaningful adjusted EBITDA turnaround (to $3.1M), substantial SG&A reductions (~$5.9M), and multiple commercial and pipeline milestones (new wins, quality audits, automation/validation progress). Offsetting these positives are continued GAAP losses ($10M), a decline in CDMO gross profit driven by product mix and lower development revenue, reliance on a large customer's 2027 inflection and multi-year timelines for commercial site transfers, and remaining work to reach the company's 25% adjusted EBITDA margin target. On balance the operational progress, improved profitability on an adjusted basis, and new business momentum outweigh the near-term challenges and timing risks.Positive Updates
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Negative Updates
Continued Net Loss
Reported net loss of $10.0M (loss per diluted share $0.29) for the quarter, improved from $16.2M ($0.53) but the company remains unprofitable on a GAAP basis.
Read all updates
Q5-2025 Updates
Positive
Negative
Strong Revenue Growth
Revenue for the 3 months ended Sept 30, 2025 was $31.1M, a 26% increase versus $24.7M in the comparable prior period. The increase was driven primarily by a $4.8M rise in HA manufacturing revenues and $1.6M increase in CDMO revenues (higher sales volumes of $2.6M partially offset by lower development revenue).
Read all positive updates
Company Guidance
Management reaffirmed transition-period guidance for May 26–Dec 31, 2025 of revenue $74–$76M, net loss of $18.4–$16.4M and adjusted EBITDA of $12–$14M; they also outlined remaining-Q4 guidance of $34–$36M (≈$35M midpoint, ~8% y/y) after estimated June revenue of $8.7M (CDMO $6.6M; HA $2.1M) and YTD (through Sept 30) stub revenue of ≈$39.8M. June adjusted EBITDA was ≈$1.5M, leaving YTD adj. EBITDA ≈$4.6M and implied Q4 adj. EBITDA guidance of $7–$9M (≈$8M midpoint), which produces an implied stub-period adjusted EBITDA margin of roughly 17% at the midpoint (vs. Q3’s ~10%: $3.1M adj. EBITDA on $31.1M revenue); management continues to target a midterm adjusted EBITDA margin of 25% and expects calendar‑2026 revenue to be weighted ~45% H1 / ~55% H2.Lifecore Biomedical Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
22
Negative
Cash Flow
44
Neutral
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Lifecore Biomedical Technical Analysis
Neutral
7.71
Price Trends
6.17
Negative
7.06
Negative
7.22
Negative
Market Momentum
-0.59
Negative
46.40
Neutral
82.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Neutral. The current price of 7.71 is above the 20-day moving average (MA) of 4.31, above the 50-day MA of 6.17, and above the 200-day MA of 7.22, indicating a neutral trend. The MACD of -0.59 indicates Negative momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 82.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFCR.
Lifecore Biomedical Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
61 Neutral | $587.01M | 22.76 | -8.22% | ― | -10.42% | ― | |
53 Neutral | $46.52M | -20.99 | -10.54% | ― | 12.21% | 69.91% | |
51 Neutral | $789.52M | -4.58 | -27.86% | ― | ― | -1.89% | |
48 Neutral | $176.89M | -9.61 | -182.11% | ― | 0.47% | -430.88% | |
47 Neutral | $141.85M | -16.52 | -46.40% | ― | 2.82% | 60.26% |
* Sector Average
LFCR
Lifecore Biomedical
4.72
-1.10
-18.90%
IRWD
Ironwood Pharma
3.60
2.66
280.95%
CPIX
Cumberland Pharmaceuticals
3.11
-0.95
-23.40%
SXTC
China SXT Pharmaceuticals
2.07
-371.43
-99.45%
DERM
Journey Medical Corp
5.19
-0.84
-13.93%
BIOA
BioAge Labs, Inc.
17.79
14.11
383.42%
Lifecore Biomedical Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Lifecore Sets 2026 Annual Meeting, Proposal Deadlines
Neutral
Mar 5, 2026
On August 1, 2025, Lifecore Biomedical’s board approved a shift in its fiscal year from one ending on the last Sunday in May to a calendar-year basis ending December 31, effective for the fiscal period from May 26, 2025 to December 31, 2025,...
Business Operations and Strategy
Lifecore Biomedical Adopts New Performance-Based Incentive Bonus Plan
Positive
Jan 16, 2026
On January 14, 2026, Lifecore Biomedical, Inc.’s Compensation Committee approved and adopted a new Incentive Bonus Plan, effective the same date, to govern bonus awards granted from that point forward. The plan establishes a structured, perf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.